Complement Inhibition: Attacking Overshooting inflammation @fter Subarachnoid Hemorrhage (CIAO@SAH trial)

Phase 2

• Conditions: Hemorrhagic stroke; 10007963

• Registration Number: NL-OMON51205
• Lead Sponsor: Haaglanden Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 128

Inclusion Criteria

- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan
- Age >= 18 years on admission
- WFNS grade 1-5

Exclusion Criteria

- Subarachnoid hemorrhage deemed most likely to *peri mesencephalic* origin
after consideration of history, clinical examination and radiological findings
(including angiographic imaging);
- Subarachnoid hemorrhage deemed most likely of post-traumatic origin after
consideration of history, clinical examination and radiological findings
(including angiographic imaging);
- Participation in another clinical therapeutic study;
- Patients with definite infaust prognosis on arrival and/or expected death
within 24 hours of admission;
- Patients with a known hereditary complement deficiency (including hereditary
angioedema);
- Patients with a history of sensibility to blood products or C1-inhibitor;
- Patients with a history of thrombosis (when known at time of inclusion);
- Pregnant woman.

Study & Design

• Study Type: Interventional
• Study Design: Not specified